Shannon King
Payments from drug & device makers
Across 383 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$776
- AstraZeneca$685
- AbbVie$629
- Boehringer Ingelheim$505
- Lilly USA, LLC$494
- Indivior Inc.$235
- plus $3K from 44 others
What the payments were for
- Food & beverage$6,278100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,280 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 55 | $60,782 |
| MounjaroTirzepatide | 30 | $40,455 |
| TrulicityDulaglutide | 26 | $34,803 |
| OzempicSemaglutide | 16 | $30,441 |
| Bydureon BciseExenatide Microspheres | 13 | $27,176 |
| EliquisApixaban | 24 | $26,497 |
| XareltoRivaroxaban | 16 | $18,363 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $18,295 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 110 | $17,175 |
| VascepaIcosapent Ethyl | 23 | $13,946 |
| Buprenorphine | 19 | $10,669 |
| FarxigaDapagliflozin Propanediol | 11 | $10,629 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,429 |
| LinzessLinaclotide | 16 | $10,027 |
| BelsomraSuvorexant | 18 | $9,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $494 | $75,25856 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $505 | $68,51067 claims |
| Novo NordiskOzempic | $776 | $30,44116 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $685 | $28,92425 claims |
| PfizerEliquis | $135 | $26,49724 claims |
| Johnson & JohnsonXarelto | $45 | $18,36316 claims |
| GSKAnoro Ellipta, Arnuity Ellipta | $188 | $15,61129 claims |
| AbbVieLinzess | $629 | $10,02716 claims |
| MerckBelsomra | $82 | $9,32318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.
Other family in Tempe
- Taylor PiontekTempe$54K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.